Implementation of the Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) study: Lessons learned for vision health systems strengthening in Sierra Leone.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
04
03
2021
accepted:
23
05
2021
entrez:
9
7
2021
pubmed:
10
7
2021
medline:
29
10
2021
Statut:
epublish
Résumé
Following the West African Ebola virus disease (EVD) outbreak of 2013-2016 and more recent EVD outbreaks in the Democratic Republic of Congo, thousands of EVD survivors are at-risk for sequelae including uveitis, which can lead to unremitting inflammation and vision loss from cataract. Because of the known risk of Ebola virus persistence in ocular fluid and the need to provide vision-restorative, safe cataract surgery, the Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) Study was implemented in Sierra Leone. During implementation of this multi-national study, challenges included regulatory approvals, mobilization, community engagement, infection prevention and control, and collaboration between multiple disciplines. In this report, we address the multifacted approach to address these challenges and the impact of implementation science research to address an urgent clinical subspecialty need in an outbreak setting. Given the patient care need to develop a protocol to evaluate ocular fluid for Ebola virus RNA persistence prior to cataract surgery, as well as protocols to provide reassurance to ophthalmologists caring for EVD survivors with cataracts, the EVICT study was designed and implemented through the work of the Ministry of Health, Sierra Leone National Eye Programme, and international partnerships. The EVICT study showed that all 50 patients who underwent ocular fluid sampling at 19 and 34 months, respectively, tested negative for Ebola virus RNA. Thirty-four patients underwent successful cataract surgery with visual acuity improvement. Here we describe the methodology for study implementation, challenges encountered, and key issues that impacted EVD vision care in the immediate aftermath of the EVD outbreak. Key aspects of the EVICT study included defining the pertinent questions and clinical need, partnership alignment with key stakeholders, community engagement with EVD survivor associations, in-country and international regulatory approvals, study site design for infection prevention and control, and thorough plans for EVD survivor follow-up care and monitoring. Challenges encountered included patient mobilization owing to transportation routes and distance of patients in rural districts. Strong in-country partnerships and multiple international organizations overcame these challenges so that lessons learned could be applied for future EVD outbreaks in West and Central Africa including EVD outbreaks that are ongoing in Guinea and Democratic Republic of Congo. The EVICT Study showed that cataract surgery with a protocol-driven approach was safe and vision-restorative for EVD survivors, which provided guidance for EVD ophthalmic surgical care. Ophthalmologic care remains a key aspect of the public health response for EVD outbreaks but requires a meticulous, yet partnered approach with international and local in-country partners. Future efforts may build on this framework for clinical care and to improve our understanding of ophthalmic sequelae, develop treatment paradigms for EVD survivors, and strengthen vision health systems in resource-limited settings.
Sections du résumé
BACKGROUND
Following the West African Ebola virus disease (EVD) outbreak of 2013-2016 and more recent EVD outbreaks in the Democratic Republic of Congo, thousands of EVD survivors are at-risk for sequelae including uveitis, which can lead to unremitting inflammation and vision loss from cataract. Because of the known risk of Ebola virus persistence in ocular fluid and the need to provide vision-restorative, safe cataract surgery, the Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) Study was implemented in Sierra Leone. During implementation of this multi-national study, challenges included regulatory approvals, mobilization, community engagement, infection prevention and control, and collaboration between multiple disciplines. In this report, we address the multifacted approach to address these challenges and the impact of implementation science research to address an urgent clinical subspecialty need in an outbreak setting.
METHODOLOGY/PRINCIPAL FINDINGS
Given the patient care need to develop a protocol to evaluate ocular fluid for Ebola virus RNA persistence prior to cataract surgery, as well as protocols to provide reassurance to ophthalmologists caring for EVD survivors with cataracts, the EVICT study was designed and implemented through the work of the Ministry of Health, Sierra Leone National Eye Programme, and international partnerships. The EVICT study showed that all 50 patients who underwent ocular fluid sampling at 19 and 34 months, respectively, tested negative for Ebola virus RNA. Thirty-four patients underwent successful cataract surgery with visual acuity improvement. Here we describe the methodology for study implementation, challenges encountered, and key issues that impacted EVD vision care in the immediate aftermath of the EVD outbreak. Key aspects of the EVICT study included defining the pertinent questions and clinical need, partnership alignment with key stakeholders, community engagement with EVD survivor associations, in-country and international regulatory approvals, study site design for infection prevention and control, and thorough plans for EVD survivor follow-up care and monitoring. Challenges encountered included patient mobilization owing to transportation routes and distance of patients in rural districts. Strong in-country partnerships and multiple international organizations overcame these challenges so that lessons learned could be applied for future EVD outbreaks in West and Central Africa including EVD outbreaks that are ongoing in Guinea and Democratic Republic of Congo.
CONCLUSIONS/SIGNIFICANCE
The EVICT Study showed that cataract surgery with a protocol-driven approach was safe and vision-restorative for EVD survivors, which provided guidance for EVD ophthalmic surgical care. Ophthalmologic care remains a key aspect of the public health response for EVD outbreaks but requires a meticulous, yet partnered approach with international and local in-country partners. Future efforts may build on this framework for clinical care and to improve our understanding of ophthalmic sequelae, develop treatment paradigms for EVD survivors, and strengthen vision health systems in resource-limited settings.
Identifiants
pubmed: 34242218
doi: 10.1371/journal.pone.0252905
pii: PONE-D-21-07252
pmc: PMC8270115
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0252905Subventions
Organisme : NEI NIH HHS
ID : K23 EY030158
Pays : United States
Organisme : NEI NIH HHS
ID : P30 EY006360
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY029594
Pays : United States
Déclaration de conflit d'intérêts
Bayer and Santen provided research award funding and grant funding, respectively with no competing relationships related to employment, consultancy, patents, products in development, and marketed products. In addition, we confirm that these grants and research award funding do not alter our adherence to all PLOS ONE policies on sharing data and materials.
Références
EBioMedicine. 2018 Apr;30:217-224
pubmed: 29622497
J Infect Dis. 2016 Oct 15;214(suppl 3):S153-S163
pubmed: 27688219
Lancet. 2017 Feb 4;389(10068):505-518
pubmed: 28017403
J Cataract Refract Surg. 2015 Jul;41(7):1461-4
pubmed: 26210053
Transl Vis Sci Technol. 2021 Jan 25;10(1):32
pubmed: 33520427
N Engl J Med. 2015 Jun 18;372(25):2423-7
pubmed: 25950269
Lancet Infect Dis. 2016 Mar;16(3):331-8
pubmed: 26725449
Lancet Infect Dis. 2016 Jun;16(6):e82-e91
pubmed: 27020309
J Pediatr Ophthalmol Strabismus. 2008 Sep-Oct;45(5):270-8
pubmed: 18825900
J Infect Dis. 2015 Oct 1;212 Suppl 2:S79-83
pubmed: 26203057
Ocul Immunol Inflamm. 2018;26(7):1128-1134
pubmed: 29993303
Science. 2014 Sep 12;345(6202):1369-72
pubmed: 25214632
Am J Ophthalmol. 2017 Mar;175:114-121
pubmed: 27998698
JAMA Ophthalmol. 2019 Sep 1;137(9):1003-1004
pubmed: 31219515
Infect Dis Poverty. 2018 Aug 16;7(1):92
pubmed: 30134982
N Engl J Med. 2019 Dec 12;381(24):2293-2303
pubmed: 31774950
N Engl J Med. 2017 Oct 12;377(15):1428-1437
pubmed: 26465681
N Engl J Med. 2019 Mar 7;380(10):924-934
pubmed: 30855742
Ophthalmology. 2017 Feb;124(2):170-177
pubmed: 27914832